AC Immune Reports Encouraging Interim Safety Data From ABATE Study Of ACI-24.060 In Down Syndrome

(RTTNews) - AC Immune SA (ACIU), a clinical-stage biopharmaceutical company, Tuesday announced encouraging interim safety data from the ABATE Phase 1b/2 study of its immunotherapy drug candidate ACI-24.060 in persons with Down syndrome (DS).

The ongoing ABATE study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060. The interim analysis was based on data from the first two cohorts of individuals with DS receiving low-dose and mid-dose ACI-24.060. Data from the interim analysis showed no serious drug-related adverse events in participants, who have been treated with ACI-24.060 for up to 1 year. Further, no cases of amyloid-related imaging abnormalities were observed in this study population. Amyloid-related imaging abnormalities are a set of brain abnormalities that appear on MRI scans of patients who are taking anti-amyloid drugs.

The company plans to open he high-dose cohort in ABATE in individuals with Down syndrome.

ACI-24.060 has already received Fast Track designation from the FDA for the treatment of Alzheimer's disease (AD). The company had previously reported positive interim safety, tolerability, and immunogenicity data from the AD cohorts of the ABATE trial.